Physician profile
Amit Bhambri
NPI 1144517020
$1,329.54
in general payments reported to CMS, 2019-2025
12 companies · $501 in 2025
The $501 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2021: $37.23 · 2022: $146 · 2023: $134 · 2024: $121 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $286.26 | 2019-2025 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $286.21 | 2019-2025 | Acuvue |
| Glaukos Corporation | $211.13 | 2025 | Idosetr |
| Alcon Vision LLC | $165.04 | 2021-2025 | Precision7 |
| Bausch & Lomb Americas INC. | $133.71 | 2023-2024 | Infuse, Zylet, Lotemax Sm |
| Dompe US, INC. | $57.03 | 2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $51.10 | 2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $49.40 | 2024 | |
| Allergan, INC. | $35.76 | 2019 | |
| Rayner Intraocular Lenses Limited | $23.31 | 2024 | Omidria, Rayone Spheric, Rayone Emv |
| Harrow Eye, LLC | $17.26 | 2024 | Vevye |
| Astellas Pharma US INC | $13.33 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Bhambri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.